Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

for the TBNET

doi:10.5588/ijtld.15.0274

Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

for the TBNET

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

© 2015 The Union.The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

Original language	English
Pages (from-to)	1524-1527
Journal	International journal of tuberculosis and lung disease
Volume	19
Issue number	12
DOIs	https://doi.org/10.5588/ijtld.15.0274
Publication status	Published - 1 Dec 2015
Externally published	Yes

Access to Document

10.5588/ijtld.15.0274

Handle.net

Persistent link

TBnet: Multidrug resistant tuberculosis in Europe
van Leth, F.
1/06/09 → 31/12/14
Project: Research

Cite this

@article{1223b31ceddd4313be7225ac43508986,

title = "Beyond multidrug-resistant tuberculosis in Europe: A TBNET study",

abstract = "{\textcopyright} 2015 The Union.The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).",

author = "G. G{\"u}nther and {Van Leth}, F. and N. Altet and M. Dedicoat and R. Duarte and G. Gualano and H. Kunst and I. Muylle and V. Spinu and S. Tiberi and P. Viiklepp and C. Lange and {for the TBNET}",

year = "2015",

month = dec,

day = "1",

doi = "10.5588/ijtld.15.0274",

language = "English",

volume = "19",

pages = "1524--1527",

journal = "International journal of tuberculosis and lung disease",

issn = "1027-3719",

publisher = "International Union against Tubercul. and Lung Dis.",

number = "12",

}

TY - JOUR

T1 - Beyond multidrug-resistant tuberculosis in Europe

T2 - A TBNET study

AU - Günther, G.

AU - Van Leth, F.

AU - Altet, N.

AU - Dedicoat, M.

AU - Duarte, R.

AU - Gualano, G.

AU - Kunst, H.

AU - Muylle, I.

AU - Spinu, V.

AU - Tiberi, S.

AU - Viiklepp, P.

AU - Lange, C.

AU - for the TBNET

PY - 2015/12/1

Y1 - 2015/12/1

N2 - © 2015 The Union.The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

AB - © 2015 The Union.The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

U2 - 10.5588/ijtld.15.0274

DO - 10.5588/ijtld.15.0274

M3 - Article

SN - 1027-3719

VL - 19

SP - 1524

EP - 1527

JO - International journal of tuberculosis and lung disease

JF - International journal of tuberculosis and lung disease

IS - 12

ER -

Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

Abstract

Access to Document

Handle.net

Fingerprint

Projects

TBnet: Multidrug resistant tuberculosis in Europe

Cite this